FY2025 EPS Forecast for Quest Diagnostics Lowered by Analyst

Quest Diagnostics Incorporated (NYSE:DGX) – Leerink Partnrs dropped their FY2025 EPS estimates for Quest Diagnostics in a report released on Tuesday, October 22nd. Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings of $9.70 per share for the year, down from their previous forecast of $10.09. The consensus estimate for Quest Diagnostics’ current full-year earnings is $8.89 per share. Leerink Partnrs also issued estimates for Quest Diagnostics’ FY2026 earnings at $10.42 EPS and FY2027 earnings at $11.50 EPS.

A number of other equities research analysts also recently issued reports on DGX. Barclays upped their price objective on shares of Quest Diagnostics from $154.00 to $168.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Evercore ISI initiated coverage on shares of Quest Diagnostics in a research report on Wednesday, August 28th. They issued an “in-line” rating and a $165.00 price objective for the company. Citigroup upped their price objective on shares of Quest Diagnostics from $165.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday. UBS Group upped their price objective on shares of Quest Diagnostics from $165.00 to $166.00 and gave the stock a “neutral” rating in a research report on Wednesday. Finally, Mizuho upped their price objective on shares of Quest Diagnostics from $160.00 to $174.00 and gave the stock an “outperform” rating in a research report on Thursday. Nine investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $163.33.

Quest Diagnostics Trading Up 0.6 %

NYSE:DGX opened at $158.00 on Friday. Quest Diagnostics has a one year low of $121.60 and a one year high of $160.95. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.00 and a quick ratio of 0.91. The firm has a 50-day moving average of $153.05 and a 200-day moving average of $144.57. The company has a market cap of $17.55 billion, a PE ratio of 21.27, a PEG ratio of 2.45 and a beta of 0.89.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Tuesday, October 22nd. The medical research company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.26 by $0.04. The company had revenue of $2.49 billion during the quarter, compared to the consensus estimate of $2.43 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period in the previous year, the firm posted $2.22 earnings per share.

Institutional Trading of Quest Diagnostics

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Quest Diagnostics by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 13,921,955 shares of the medical research company’s stock worth $1,853,151,000 after purchasing an additional 345,754 shares in the last quarter. Davis Selected Advisers lifted its stake in Quest Diagnostics by 0.4% in the 2nd quarter. Davis Selected Advisers now owns 2,390,828 shares of the medical research company’s stock worth $327,257,000 after purchasing an additional 9,665 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Quest Diagnostics by 6.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,109,515 shares of the medical research company’s stock worth $288,758,000 after purchasing an additional 129,395 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its stake in Quest Diagnostics by 2.1% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 748,680 shares of the medical research company’s stock worth $115,621,000 after purchasing an additional 15,047 shares in the last quarter. Finally, Nuance Investments LLC lifted its stake in Quest Diagnostics by 13.1% in the 1st quarter. Nuance Investments LLC now owns 681,636 shares of the medical research company’s stock worth $90,733,000 after purchasing an additional 79,152 shares in the last quarter. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Quest Diagnostics

In related news, SVP Karthik Kuppusamy sold 1,990 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total transaction of $304,987.40. Following the sale, the senior vice president now directly owns 11,459 shares in the company, valued at approximately $1,756,206.34. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.79% of the stock is currently owned by corporate insiders.

Quest Diagnostics Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, October 21st. Investors of record on Friday, October 4th were paid a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.90%. The ex-dividend date was Friday, October 4th. Quest Diagnostics’s payout ratio is currently 40.38%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.